Bayard L. Powell, MD


CPI-613 in Combination With High Dose ARA-C and Mitoxantrone

Bayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).

Ben Jones


Effects of the Affordable Care Act

Ben Jones from McKesson Specialty Health discusses how the affordable care act will affect oncologists.

Ben Leach


Immunotherapy in Melanoma

At the 11th International Congress on Targeted Therapies in Cancer, The International Journal of Targeted Therapies in Cancer spoke with Dr. Sosman about his conference presentation on advances in immunotherapy in melanoma.

Benjamin G. Neel, MD


Future of Immunotherapy in Various Tumor Types

Benjamin G. Neel, MD, faculty, Department of Medicine, Perlmutter Cancer Center, NYU School of Medicine, discusses the future of immunotherapy and how it could play a role in various tumor types.

Benjamin G. Neel, MD, PhD


Assessing Recent Progress Toward Cancer Cures at Perlmutter Cancer Center

Benjamin G. Neel, MD, PhD, director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone, discusses how his institution has changed vastly over the last few years, with an increasing number of clinical trials available for patients with lung cancer and other cancers. Clinical trials are often the best option for cancers where the outcomes with conventional treatments may be uncertain, Neel says.

Benjamin J. Drapkin, MD, PhD


Co-Clinical Trial of Olaparib and Temozolomide in SCLC PDX Models

Benjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.

Benjamin Levy, MD


Immunotherapy Advances Lung Cancer Treatment Landscape

Benjamin Levy, MD, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.

Benjamin O. Anderson, MD


The Global Unmet Need in Breast Cancer Care

Benjamin O. Anderson, MD, Seattle Cancer Care Alliance, discusses the current global unmet need for the treatment of patients with breast cancer.

Benjamin P. Levy, MD


Targeted Therapies Show Activity in ROS1 Fusion-Positive Lung Cancer

Benjamin P. Levy, MD, discusses biomarkers that have led to the development therapies with high response rates in lung cancer.

Benjamin Smith, MD


Dr. Benjamin Smith on Complication Burdens in Different Local Treatments for Breast Cancer

​Benjamin Smith, MD, discusses a recent study looking at local treatments in breast cancer and the complication burdens associated with them. Smith says that any complications arising in patients with breast cancer within 2 years are strongly associated with their treatments.

Benjamin Weinberg, MD


Targeted Therapies Showing Promise in Colorectal Cancer

Benjamin Weinberg, MD, discusses novel agents that may impact the treatment landscape for colorectal cancer once made available in the community setting.

Beth Fand Incollingo


Sotorasib Shows Early Activity in Advanced Non–Small Cell Lung Cancer

In patients with non–small cell lung cancer harboring a KRAS G12C mutation, an aberration without any FDA approved treatment options, a study showed that the investigation agent, sotorasib achieved encouraging antitumor activity.

Beth Overmoyer, MD


Obesity as a Risk Factor for Inflammatory Breast Cancer

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, discusses obesity as a risk factor for inflammatory breast cancer.

Betty Hamilton, MD


Dr. Betty Hamilton on Molecular Mutations in AML and MDS

Betty Hamilton, MD, discusses TET2 mutations in molecular mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) on allogeneic hematopoietic cell transplant outcomes.

Bianca D. Santomasso, MD, PhD


Challenges Remain to be Addressed With CAR T-Cell Therapy in DLBCL

Bianca D. Santomasso, MD, PhD, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma with CAR T-cell therapy.

Bilal Piperdi, MD


<em>RICTOR</em> Amplification in Lung Cancer

Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.

Bill Loguidice


New Collaboration Forms for Immunotherapy Regimens in Hematologic Malignancies

MedImmune Limited, a subsidiary of AstraZeneca PLC, and Celgene International II Sàrl, a subsidiary of Celgene Corporation, have formed a strategic collaboration for the development and commercialization of AstraZeneca’s anti-programmed cell death-ligand 1 (PD-L1) agent MEDI4736.

Bill Wimbiscus


Patient Adherence, a Challenge of Oral Chemotherapy

Advances in oral chemotherapy are radically changing the way doctors, pharmacists, and their patients manage cancer, yet oral chemotherapy requires the patients themselves to correctly administer the drug, causing issues in patient adherence.<br /> &nbsp;

Bishoy Faltas, MD


Exploring the Role of Genomic Testing in Urothelial Cancer

Bishoy M. Faltas, MD, discusses the current use of genomic testing to guide urothelial cancer treatment.

Bishoy M. Faltas, MD


Tumor Tissue Analysis Provides Insight Into Tumor Heterogeneity

Bishoy M. Faltas, MD, discusses the significance of studying the response of tumor tissue to mutation-targeted agents in urothelial cancer.

Bo Gamble


Gamble Discusses Exciting Topics at the Upcoming 2018 Community Oncology Conference

Robert &quot;Bo&quot; Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), discusses some of the exciting topics that will be covered during the upcoming 2018 Community Oncology Conference.&nbsp;

Bonnie Addario


The Side Effects of Lung Cancer Treatment

Bonnie Addario, a lung cancer survivor, discusses toxicities involved during lung cancer treatment.

Bonnie Gillis


Chemotherapy Safe After Radium-223 for Men With mCRPC

The explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.

Boris Kuvshinoff II, MD, MBA


Microwave Ablation for the Treatment of Liver Cancer

Boris Kuvshinoff II, MD, MBA, associate professor, Division of Gastrointestinal/Endocrine Surgery, Department of Surgical Oncology, director, Liver and Pancreas Tumor Center, Roswell Park Cancer Institute, discusses microwave ablation therapy for the treatment of liver cancer.